{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:28:49Z","timestamp":1781188129912,"version":"3.54.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.prp.2023.154336","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T11:30:49Z","timestamp":1674473449000},"page":"154336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types"],"prefix":"10.1016","volume":"243","author":[{"given":"Giuseppa","family":"Zannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Orditura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Vietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Accardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zito Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154336_bib1","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis","volume":"95","author":"Baretta","year":"2016","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.prp.2023.154336_bib2","first-page":"862","article-title":"BRCA genes: BRCA 1 and BRCA 2","volume":"23","author":"Varol","year":"2018","journal-title":"J. BUON"},{"key":"10.1016\/j.prp.2023.154336_bib3","article-title":"BRCA1- and BRCA2-associated hereditary breast and ovarian cancer","author":"Petrucelli","year":"2022","journal-title":"GeneReviews\u00ae"},{"key":"10.1016\/j.prp.2023.154336_bib4","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"BRCA1 and BRCA2 Cohort Consortium, Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.prp.2023.154336_bib5","unstructured":"BRCA Gene Mutations: Cancer Risk and Genetic Testing. National Cancer Institute. Available at: \u3008https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ejhg.2016.95","article-title":"Finding all BRCA pathogenic mutation carriers: best practice models","volume":"24","author":"Hoogerbrugge","year":"2016","journal-title":"Eur. J. Hum. Genet"},{"key":"10.1016\/j.prp.2023.154336_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265387","article-title":"Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations","volume":"17","author":"Annoni","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2023.154336_bib8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jamaoncol.2020.2134","article-title":"Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA)","volume":"6","author":"Silvestri","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib9","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/EDBK_238977","article-title":"The role of BRCA testing in hereditary pancreatic and prostate cancer families","volume":"39","author":"Pilarski","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.prp.2023.154336_bib11","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdw327","article-title":"ESMO Guidelines Committee, Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","volume":"27","author":"Paluch-Shimon","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.prp.2023.154336_bib14","unstructured":"Aiom Guidelines: recommendations for implementing BRCA testing. Available at: \u3008https:\/\/www.fondazioneaiom.it\/raccomandazioni-per-limplementazione-del-test-brca-predittivo-e-preventivo-nei-tumori-della-mammella-dellovaio-del-pancreas-e-della-prostata\/\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib15","first-page":"66","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994"},{"key":"10.1016\/j.prp.2023.154336_bib16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.prp.2023.154336_bib17","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.prp.2023.154336_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.prp.2023.154336_bib19","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","article-title":"The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability","volume":"25","author":"Gudmundsdottir","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154336_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1126\/science.272.5258.123","article-title":"Location of BRCA1 in human breast and ovarian cancer cells","volume":"272","author":"Scully","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.prp.2023.154336_bib22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/MCB.17.1.444","article-title":"Localization of BRCA1 and a splice variant identifies the nuclear localization signal","volume":"17","author":"Thakur","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.prp.2023.154336_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.18632\/oncotarget.12306","article-title":"Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154336_bib24","first-page":"3299","article-title":"Role for ATM in DNA damage-induced phosphorylation of BRCA1","volume":"60","author":"Gatei","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.onc.1206176","article-title":"Homologous repair of DNA damage and tumorigenesis: the BRCA connection","volume":"21","author":"Jasin","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154336_bib26","unstructured":"BRCA Exchange. Available at: \u3008https:\/\/brcaexchange.org\/\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib27","unstructured":"Catalogue of Somatic Mutations in Cancer (COSMIC) database. Available at: \u3008https:\/\/cancer.sanger.ac.uk\/cosmic\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib28","unstructured":"Leiden Open Variation Database (LOVD). Available at: \u3008https:\/\/www.lovd.nl\/\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00928437","article-title":"Poly(ADP-ribose): historical perspective","volume":"138","author":"Sugimura","year":"1994","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.prp.2023.154336_bib30","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.phrs.2018.09.031","article-title":"PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection","volume":"137","author":"McQuade","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.prp.2023.154336_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/ijc.IJC_53_21","article-title":"A review on mechanisms of resistance to PARP inhibitors","volume":"59","author":"Desai","year":"2022","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib33","unstructured":"Drug Approvals and Databases. U.S. Food and Drug Administration Web site. Available at: \u3008https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2741\/4185","article-title":"Breast cancer genes: beyond BRCA1 and BRCA2","volume":"18","author":"Filippini","year":"2013","journal-title":"Front. Biosci. (Landmark Ed. )"},{"key":"10.1016\/j.prp.2023.154336_bib35","doi-asserted-by":"crossref","first-page":"70113","DOI":"10.18632\/oncotarget.12158","article-title":"BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154336_bib36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/bjc.2016.32","article-title":"Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis","volume":"114","author":"Phi","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib37","first-page":"1","article-title":"Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know","volume":"90","author":"Franceschini","year":"2019","journal-title":"Ann. Ital. Chir."},{"key":"10.1016\/j.prp.2023.154336_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:JOMG.0000048770.90334.3b","article-title":"The genetic epidemiology of breast cancer genes","volume":"9","author":"Thompson","year":"2004","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"key":"10.1016\/j.prp.2023.154336_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/928562","article-title":"A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer","author":"Karami","year":"2013","journal-title":"Biomed. Res. Int"},{"key":"10.1016\/j.prp.2023.154336_bib40","article-title":"Are BRCA1- and BRCA2-related breast cancers associated with increased mortality","volume":"6","author":"Evans","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(14)70364-X","article-title":"Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry","volume":"15","author":"Brewster","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib42","first-page":"2","year":"2017","journal-title":"Hered. Breast \/Or. Ovarian Cancer Syndr."},{"key":"10.1016\/j.prp.2023.154336_bib43","unstructured":"Norwegian Breast Cancer Group: National guidelines for diagnostics, treatment and follow-up of patients with breast cancer. Available at: \u3008http:\/\/nbcg.no\/retningslinjer\/content\/text_7aca3287\u20137ec2\u20134c46\u201385c3\u20131ea97fd42377\/1455823579701\/brystkreftbehandlingsprogram_10_02.pdf\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib44","unstructured":"National Institute for Health and Care Excellence: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer: NICE guidelines. Available at: \u3008https:\/\/www.nice.org.uk\/guidance\/cg164\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12687-013-0166-9","article-title":"BRCA sequencing and large rearrangement testing in young Black women with breast cancer","volume":"5","author":"Pal","year":"2014","journal-title":"J. Community Genet"},{"key":"10.1016\/j.prp.2023.154336_bib46","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib47","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1586\/14737140.2015.1090879","article-title":"Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer","volume":"15","author":"Lerner-Ellis","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.prp.2023.154336_bib48","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.prp.2023.154336_bib49","unstructured":"ACS guidelines: Genetic Counseling and Testing for Breast Cancer Risk. Available at: \u3008https:\/\/www.cancer.org\/cancer\/breast-cancer\/risk-and-prevention\/genetic-testing.html\u3009."},{"key":"10.1016\/j.prp.2023.154336_bib50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3343\/alm.2020.40.2.114","article-title":"BRCA1\/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies","volume":"40","author":"Lee","year":"2020","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.prp.2023.154336_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12907-015-0004-6","article-title":"A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing","volume":"15","author":"Ellison","year":"2015","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/j.prp.2023.154336_bib52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ijc.29021","article-title":"MicroRNA expression signatures for the prediction of BRCA1\/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors","volume":"136","author":"Tanic","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib53","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ijc.30143","article-title":"Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis","volume":"139","author":"Bu","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib54","doi-asserted-by":"crossref","first-page":"483","DOI":"10.21037\/tcr.2019.03.02","article-title":"BRCA1\/2 mutation spectrum in Chinese early-onset breast cancer","volume":"8","author":"Shen","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.prp.2023.154336_bib55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib56","first-page":"632","article-title":"Estimating the risk of ovarian cancer","volume":"80","author":"Ebell","year":"2009","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.prp.2023.154336_bib57","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib58","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/genes12071050","article-title":"Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location","volume":"12","author":"Sekine","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.prp.2023.154336_bib59","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/j.seminoncol.2016.10.001","article-title":"Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer","volume":"43","author":"Cobain","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib60","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib61","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14737140.2016.1247699","article-title":"Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management","volume":"16","author":"Weinberger","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.prp.2023.154336_bib62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: testing, implications and treatment considerations","volume":"9","author":"Neff","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1574892813666180305165256","article-title":"PARP Inhibitors in Ovarian Cancer","volume":"13","author":"Mittica","year":"2018","journal-title":"Recent. Pat. Anticancer Drug Disco"},{"key":"10.1016\/j.prp.2023.154336_bib64","doi-asserted-by":"crossref","first-page":"61845","DOI":"10.18632\/oncotarget.11259","article-title":"Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples","volume":"7","author":"Enyedi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154336_bib65","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.18632\/oncotarget.6834","article-title":"BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing","volume":"2","author":"Mafficini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154336_bib66","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/humu.23137","article-title":"Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas","volume":"38","author":"Weren","year":"2017","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.prp.2023.154336_bib67","doi-asserted-by":"crossref","first-page":"85529","DOI":"10.18632\/oncotarget.13456","article-title":"Prevalence and clinical significance of BRCA1\/2 germline and somatic mutations in Taiwanese patients with ovarian cancer","volume":"7","author":"Chao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154336_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152595","article-title":"BRCA1\/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients","volume":"215","author":"Lee","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2023.154336_bib69","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jclinpath-2020-206840","article-title":"Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations","volume":"74","author":"Rivera","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.prp.2023.154336_bib70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fonc.2020.00295","article-title":"Germline and Somatic BRCA1\/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer","volume":"10","author":"You","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib71","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3390\/cancers14061434","article-title":"Real-World Data on Detection of Germline and Somatic Pathogenic\/Likely Pathogenic Variants in BRCA1\/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing","volume":"14","author":"Stegel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2023.154336_bib72","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study","volume":"3","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14728222.2021.1951226","article-title":"Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology","volume":"25","author":"Boussios","year":"2021","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.prp.2023.154336_bib74","doi-asserted-by":"crossref","first-page":"12628","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154336_bib75","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib76","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"UKGPCS Collaborators, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib77","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2023.154336_bib78","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib79","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2023.154336_bib81","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.3390\/cancers13225697","article-title":"Pathogenic BRCA variants as biomarkers for risk in prostate cancer","volume":"13","author":"McNevin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2023.154336_bib82","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Beltran","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2023.154336_bib83","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/pros.23219","article-title":"Study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling","volume":"76","author":"Cheng","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.prp.2023.154336_bib84","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1038\/s41598-017-04897-x","article-title":"Mutations in BRCA2 and taxane resistance in prostate cancer","volume":"7","author":"Nientiedt","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2023.154336_bib85","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00262-019-02393-x","article-title":"The BRCA2 mutation status shapes the immune phenotype of prostate cancer","volume":"68","author":"Jenzer","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2023.154336_bib86","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1200\/PO.19.00388","article-title":"STAMPEDE Investigators, Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial","volume":"4","author":"Gilson","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib87","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1038\/s41388-020-1280-x","article-title":"Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians","volume":"39","author":"Yadav","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154336_bib88","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3748\/wjg.v27.i17.1943","article-title":"BRCA mutated pancreatic cancer: A change is coming","volume":"27","author":"Rosen","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2023.154336_bib89","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.prp.2023.154336_bib90","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.seminoncol.2016.09.002","article-title":"Familial pancreatic cancer","volume":"43","author":"Petersen","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib91","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00432-018-2666-9","article-title":"Emerging strategies in BRCA-positive pancreatic cancer","volume":"144","author":"Kowalewski","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib92","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","article-title":"International Cancer of Pancreas Screening (CAPS) Consortium, International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer","volume":"62","author":"Canto","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.prp.2023.154336_bib93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ajg.2014.435","article-title":"American College of Gastroenterology, ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes","volume":"110","author":"Syngal","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.prp.2023.154336_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103033","article-title":"Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes","volume":"60","author":"Mizukami","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2023.154336_bib95","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2023.154336_bib96","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0000000000000554","article-title":"PARP inhibitors in pancreatic cancer","volume":"27","author":"Brown","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.prp.2023.154336_bib97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-20-0365","article-title":"Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer","volume":"20","author":"Parsels","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2023.154336_bib98","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-15-0426","article-title":"Australian Pancreatic Cancer Genome Initiative (APGI), Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial","volume":"21","author":"Chantrill","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154336_bib99","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1038\/srep08829","article-title":"Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas","volume":"5","author":"Furukawa","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2023.154336_bib100","first-page":"1046","article-title":"Feasibility of BRCA1\/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series","volume":"11","author":"Bruno","year":"2021","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.prp.2023.154336_bib101","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cam4.3679","article-title":"Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes","volume":"10","author":"Lu","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.prp.2023.154336_bib102","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1538-7445.AM2021-867","article-title":"Incidence of molecular alterations in KRAS and other known cancer genes in patients with pancreatic cancer assessed with a commercial genomic profiling panel compared to TCGA results [Abstract 867]","volume":"81","author":"Le","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103897","article-title":"Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer","volume":"77","author":"Zhang","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2023.154336_bib104","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.prp.2023.154336_bib105","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.AOG.0000187892.78392.3f","article-title":"BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?","volume":"106","author":"Cass","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.prp.2023.154336_bib106","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.31557\/APJCP.2020.21.8.2381","article-title":"Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study","volume":"21","author":"Lertkhachonsuk","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.prp.2023.154336_bib107","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","article-title":"Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations","volume":"21","author":"Levine","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.prp.2023.154336_bib109","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/jjco\/hyy095","article-title":"Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women","volume":"48","author":"Sakurada","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib110","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/IGC.0b013e318257b936","article-title":"Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population","volume":"22","author":"Bacha","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib111","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00404-008-0678-4","article-title":"Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics","volume":"278","author":"Iavazzo","year":"2008","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.prp.2023.154336_bib112","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamasurg.2013.1006","article-title":"Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer","volume":"148","author":"Sitzmann","year":"2013","journal-title":"JAMA Surg."},{"key":"10.1016\/j.prp.2023.154336_bib113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/gyno.2002.6853","article-title":"Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women","volume":"88","author":"Menczer","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103425","article-title":"Molecular landscape of Hereditary Melanoma","volume":"164","author":"Ribeiro Moura Brasil Arnaut","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.prp.2023.154336_bib115","first-page":"1564","article-title":"J.F. Fraumeni Jr, Second malignant neoplasms among long-term survivors of ovarian cancer","volume":"56","author":"Travis","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib116","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ijc.1542","article-title":"Association of ocular melanoma with breast cancer but not with cutaneous melanoma: results from the Swedish Family-Cancer Database","volume":"94","author":"Hemminki","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<325::AID-IJC3>3.0.CO;2-G","article-title":"Germline brca2 sequence variants in patients with ocular melanoma","volume":"82","author":"Sinilnikova","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib118","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","article-title":"Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations","volume":"11","author":"Moran","year":"2012","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib119","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1167\/iovs.02-0026","article-title":"Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma","volume":"44","author":"Hearle","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prp.2023.154336_bib120","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/bjd.13626","article-title":"Skin cancer risk in BRCA1\/2 mutation carriers","volume":"172","author":"Gumaste","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.prp.2023.154336_bib121","doi-asserted-by":"crossref","first-page":"75","DOI":"10.17992\/lbl.2014.02.531","article-title":"Krabbamein \u00ed ristli og enda\u00fearmi [Colorectal cancer - review]","volume":"100","author":"Haraldsdottir","year":"2014","journal-title":"Laeknabladid"},{"key":"10.1016\/j.prp.2023.154336_bib122","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1054\/bjoc.2000.1598","article-title":"The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients","volume":"84","author":"Chen-Shtoyerman","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2023.154336_bib123","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jnci\/djh006","article-title":"Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer","volume":"96","author":"Kirchhoff","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2023.154336_bib124","first-page":"559","article-title":"Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study","volume":"20","author":"Drucker","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.prp.2023.154336_bib125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djh008","article-title":"BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer","volume":"96","author":"Niell","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2023.154336_bib126","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cge.12497","article-title":"BRCA1 and BRCA2 mutations and the risk for colorectal cancer","volume":"87","author":"Sopik","year":"2015","journal-title":"Clin. Genet."},{"key":"10.1016\/j.prp.2023.154336_bib127","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2017.08.004","article-title":"Guidance statement On BRCA1\/2 tumor testing in ovarian cancer patients","volume":"44","author":"Capoluongo","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.prp.2023.154336_bib128","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/humu.23375","article-title":"An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice","volume":"39","author":"Ellison","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.prp.2023.154336_bib129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cca.2018.02.012","article-title":"A comprehensive BRCA1\/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis","volume":"480","author":"Concolino","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.prp.2023.154336_bib130","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/ijms19040961","article-title":"A Whole Germline BRCA2 Gene Deletion: How to Learn from CNV In Silico Analysis","volume":"19","author":"Scaglione","year":"2018","journal-title":"Int. J. Mol. Sci."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:54:05Z","timestamp":1759733645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":130,"alternative-id":["S0344033823000365"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154336","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154336"}}